Results 91 to 100 of about 807 (164)

Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies

Influenza and Other Respiratory Viruses, Volume 18, Issue 12, December 2024.
ABSTRACT Enterovirus‐D68 (EV‐D68) was first identified in 1962 in pediatric patients with acute respiratory conditions in California, USA (US). From the 1970s to 2005, EV‐D68 was underestimated due to limited data and serotyping methods. In 2014, the United States experienced outbreaks of acute flaccid myelitis (AFM) in children EV‐D68 positive.
Nida Kalam, Vinod R. M. T. Balasubramaniam   +1 more
wiley   +1 more source

Public health equity in information asymmetry: phenomenological studies upon SARS-CoV-2 super-virus mutation [PDF]

, 2022
In the context of SARS-CoV-2 crises, the phenomenological studies analyze the market phenomenon of People’s Republic of China (PRC) in public health. With PRC’s diplomatic behaviors around the national, international, and global public health crises, the
Pachankis, Yang
core   +1 more source

Early Versus Delayed Usage of Paxlovid in Severe Omicron‐Infected Patients With Hypoxemia: A Prospective Multiple‐Center Cohort Study

Health Science Reports, Volume 7, Issue 11, November 2024.
ABSTRACT Background and Aims Early stage administration of Paxlovid has been shown to improve the prognosis of mild to moderate COVID‐19 patients with high risk. However, few evidence was validated in severe COVID‐19 patients with hypoxemia. It is also unclear whether delayed usage of Paxlovid affected prognosis in COVID‐19 patients or not.
Yu‐Ji Wang, Xi‐Yan Ma, Xiao‐Ying Wei, Meng‐Lan Zhang, Nan Su, Jun‐Hong Jiang, Guo‐Peng Xu, Ran Wang, Da‐Xiong Zeng   +8 more
wiley   +1 more source

A Retrospective Analysis of Azvudine in Patients with COVID-19 and Pre-existing Cancer

Journal of Cancer
Objectives: Azvudine has been recommended as a potential treatment for the recently discovered Coronavirus disease (COVID-19) in 2019. However, the effectiveness of Azvudine in individuals who have both COVID-19 and pre-existing cancer remains uncertain.
Li, Fangyu, Zheng, Keao, Qi, Xueyan, Cui, Kaixia, Yang, Jing, Hao, Zhiying   +5 more
openaire   +2 more sources

Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study

BMC Infectious Diseases
Background Azvudine has clinical benefits and acceptable safety against COVID-19, including in patients with comorbidities, but there is a lack of available data for its use in older adult patients.
Zhiguo Zhou, He Zheng, Gui’e Xiao, Xiangping Xie, Jiaxi Rang, Danhong Peng   +5 more
doaj   +1 more source

Azvudine (FNC): a promising clinical candidate for COVID-19 treatment [PDF]

Signal Transduction and Targeted Therapy, 2020
Yu, Bin, Chang, Junbiao
openaire   +2 more sources

A Pragmatic Review of COVID-19 Management: Therapeutic Approaches, Challenges, and Recommendations [PDF]

The coronavirus disease 2019 (COVID-19), caused by the novel RNA virus SARS-CoV-2, was declared a global pandemic on 11 March 2020. Its rapid worldwide transmission highlighted the urgent need for effective clinical management strategies.
Linisha.N.M, Madhumitha. N, Revathi K, Subha. S. C, Swathi T   +4 more
core   +1 more source

A Study on the Efficacy of Early Application of Azvudine in Viral Myocarditis under the Epidemic

Journal of Medicines Development Sciences
Objective: To explore the efficacy of early application of Azvudine in patients with viral myocarditis during the epidemic. Methods: Sixty patients diagnosed with "infection complicated with myocarditis" in our hospital from December 2022 to December 2023 were selected and randomly divided into an intervention group and a control ...
Minjie Wu, Linlin Tan, Anjian Yan
openaire   +1 more source

Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice [PDF]

Cardiovascular disease is associated with progression to severe COVID-19 and patients with the condition are among those in whom early antiviral therapy should be warranted.
Di Lenarda A., Ferri N., Lanzafame M., Montuori E. A., Pacelli L.   +4 more
core   +1 more source

Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval [PDF]

The global research and pharmaceutical community rapidly mobilized to develop treatments for coronavirus disease 2019 (COVID-19). Existing treatments have been repurposed and new drugs have emerged.
Cho, SK, Choi, AY, Choi, HS, Kopp, JB, Winkler, CA   +4 more
core   +1 more source